Celltrion Taps New Contract Business As Route To Novel Drugs
Celltrion has opted to use its biologics CDMO business as part of its first open innovation strategy to access and develop novel drugs by sharing development costs or licensing in product candidates, a move seen as unique among biosimilar companies.
You may also be interested in...
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a global leader in antibody biosimilars. In this instalment of Scrip’s Leadership Series, CEO Woo Sung Kee talks about what it has taken for the company and its top management to achieve such rapid growth, its ambitions to enter the global top 10 biotech firms, and his own work philosophy.
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.